GlassScriptPhysician profile
Marco A Rabines
NPI 1780833038
$6,418.10
in general payments reported to CMS, 2019-2025
17 companies · $3,309 in 2025
The $3,309 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $15.73 · 2021: $268 · 2022: $56.69 · 2023: $506 · 2024: $1,965 · 2025: $3,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,668 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.31 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,471.08 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,035.44 | 2019-2025 | Invega, Invega Sustenna, Spravato |
| Abbvie INC. | $996.86 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $792.02 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $423.02 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $394.16 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $323.70 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.68 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $172.60 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $161.72 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $136.83 | 2025 | Fanapt |
| Indivior INC. | $96.16 | 2019-2025 | Sublocade, Perseris |
| Lundbeck LLC | $88.65 | 2023 | Rexulti |
| Luye Pharma (USA) LTD. | $50.66 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $16.63 | 2023 | Loreev Xr, Sertraline Hcl |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.57 | 2023 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Rabines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.